63,137 results match your criteria treatment parkinson's


Hydroxytyrosol as anti-parkinsonian molecule: Assessment using in-silico and MPTP-induced Parkinson's disease model.

Biomed Pharmacother 2021 Apr 18;139:111525. Epub 2021 Apr 18.

Department of Biochemistry, Basic Medical Sciences Block-II, Panjab University, Chandigarh 160014, India. Electronic address:

3-Hydroxytyrosol (HXT) is a natural polyphenol present in extra virgin olive oil. It is a key component of Mediterranean diet and is known for its strong antioxidant activity. The present study evaluated the potential of HXT as an anti-parkinsonian molecule in terms of its ability to inhibit MAO-B and thereby maintaining dopamine (DA) levels in Parkinson's disease (PD). Read More

View Article and Full-Text PDF

MiR-30a-5p Regulates GLT-1 Function via a PKCα-Mediated Ubiquitin Degradation Pathway in a Mouse Model of Parkinson's Disease.

ACS Chem Neurosci 2021 Apr 21. Epub 2021 Apr 21.

Department of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, China.

Glutamate excitotoxicity is caused by dysfunctional glutamate transporters and plays an important role in the pathogenesis of Parkinson's disease (PD); however, the mechanisms that underlie the regulation of glutamate transporters in PD are still not fully elucidated. MicroRNAs(miRNA), which are abundant in astrocytes and neurons, have been reported to play key roles in regulating the translation of glutamate-transporter mRNA. In this study, we hypothesized that the miR-30a-5p contributes to the pathogenesis of PD by regulating the ubiquitin-mediated degradation of glutamate transporter 1 (GLT-1). Read More

View Article and Full-Text PDF

Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.

Metab Brain Dis 2021 Apr 21. Epub 2021 Apr 21.

Department of Physical Therapy, College of Allied Health Sciences, Augusta University, 987 St. Sebastian Way, Augusta, GA, 30912, USA.

Parkinson's disease (PD) is one of the most common neurodegenerative diseases after Alzheimer's disease (AD), afflicting adults above the age of sixty irrespective of gender, race, ethnicity, and social status. PD is characterized by motor dysfunctions, displaying resting tremor, rigidity, bradykinesia, and postural imbalance. Non-motor symptoms, including rapid eye movement (REM) behavior disorder, constipation, and loss of sense of smell, typically occur many years before the appearance of the PD motor symptoms that lead to a diagnosis. Read More

View Article and Full-Text PDF

Principal Component Analysis of Striatal and Extrastriatal D2 Dopamine Receptor Positron Emission Tomography in Manganese Exposed Workers.

Toxicol Sci 2021 Apr 20. Epub 2021 Apr 20.

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.

The relationships between the neurotoxicant manganese (Mn), dopaminergic pathology and parkinsonism remain unclear. Therefore, we used [11C](N-methyl)benperidol (NMB) positron emission tomography (PET) to investigate the associations between Mn exposure, striatal and extrastriatal D2 dopamine receptors (D2R), and motor function in 54 workers with a range of Mn exposure. Cumulative Mn exposure was estimated from work histories, and all workers were examined by a movement specialist and completed a Grooved Pegboard test (GPT). Read More

View Article and Full-Text PDF

The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting.

Clin Sci (Lond) 2021 Apr;135(8):1015-1051

Department of Pharmacology and Toxicology, American University of Beirut, Beirut, Lebanon.

Antithrombotic drugs are widely used for primary and secondary prevention, as well as treatment of many cardiovascular disorders. Over the past few decades, major advances in the pharmacology of these agents have been made with the introduction of new drug classes as novel therapeutic options. Accumulating evidence indicates that the beneficial outcomes of some of these antithrombotic agents are not solely related to their ability to reduce thrombosis. Read More

View Article and Full-Text PDF

Ageing promotes pathological alpha-synuclein propagation and autonomic dysfunction in wild-type rats.

Brain 2021 Apr 20. Epub 2021 Apr 20.

Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.

Neuronal aggregates of misfolded alpha-synuclein protein are found in the brain and periphery of patients with Parkinson's disease. Braak and colleagues have hypothesized that the initial formation of misfolded alpha-synuclein may start in the gut, and then spread to the brain via peripheral autonomic nerves hereby affecting several organs, including the heart and intestine. Age is considered the greatest risk factor for Parkinson's disease, but the effect of age on the formation of pathology and its propagation has not been studied in detail. Read More

View Article and Full-Text PDF

Getting into a "Flow" state: a systematic review of flow experience in neurological diseases.

J Neuroeng Rehabil 2021 Apr 20;18(1):65. Epub 2021 Apr 20.

Neurocenter, Luzerner Kantonsspital, Spitalstrasse 31, 6000, Luzern 16, Switzerland.

Background: Flow is a subjective psychological state that people report when they are fully involved in an activity to the point of forgetting time and their surrounding except the activity itself. Being in flow during physical/cognitive rehabilitation may have a considerable impact on functional outcome, especially when patients with neurological diseases engage in exercises using robotics, virtual/augmented reality, or serious games on tablets/computer. When developing new therapy games, measuring flow experience can indicate whether the game motivates one to train. Read More

View Article and Full-Text PDF

Administration of quercetin improves mitochondria quality control and protects the neurons in 6-OHDA-lesioned Parkinson's disease models.

Aging (Albany NY) 2021 Apr 20;13. Epub 2021 Apr 20.

Department of Neurology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China.

Mounting evidence suggests that mitochondrial dysfunction and impaired mitophagy lead to Parkinson's disease (PD). Quercetin, one of the most abundant polyphenolic flavonoids, displays many health-promoting biological effects in many diseases. We explored the neuroprotective effect of quercetin in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of PD and in 6-OHDA-treated PC12 cells. Read More

View Article and Full-Text PDF

Sirtuin Acetylation and Deacetylation: a Complex Paradigm in Neurodegenerative Disease.

Mol Neurobiol 2021 Apr 20. Epub 2021 Apr 20.

Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.

Sirtuins are the class III of histone deacetylases that depend on nicotinamide adenine dinucleotide for their activity. Sirtuins can influence the progression of neurodegenerative disorders by switching between deacetylation and acetylation processes. Histone acetylation occurs when acetyl groups are added to lysine residues on the N-terminal part of histone proteins. Read More

View Article and Full-Text PDF

Pharmacological inhibition of nSMase2 reduces brain exosome release and α-synuclein pathology in a Parkinson's disease model.

Mol Brain 2021 Apr 19;14(1):70. Epub 2021 Apr 19.

Drug Discovery Lab, Department of Neurology, University of California, Los Angeles, CA, 90095, USA.

Aim: We have previously reported that cambinol (DDL-112), a known inhibitor of neutral sphingomyelinase-2 (nSMase2), suppressed extracellular vesicle (EV)/exosome production in vitro in a cell model and reduced tau seed propagation. The enzyme nSMase2 is involved in the production of exosomes carrying proteopathic seeds and could contribute to cell-to-cell transmission of pathological protein aggregates implicated in neurodegenerative diseases such as Parkinson's disease (PD). Here, we performed in vivo studies to determine if DDL-112 can reduce brain EV/exosome production and proteopathic alpha synuclein (αSyn) spread in a PD mouse model. Read More

View Article and Full-Text PDF

Genotype-driven therapeutic developments in Parkinson's disease.

Mol Med 2021 Apr 19;27(1):42. Epub 2021 Apr 19.

Department of Neurology, University Medical Center Schleswig-Holstein, Campus Lübeck, Lübeck, Germany.

Background: Remarkable advances have been reached in the understanding of the genetic basis of Parkinson's disease (PD), with the identification of monogenic causes (mPD) and a plethora of gene loci leading to an increased risk for idiopathic PD. The expanding knowledge and subsequent identification of genetic contributions fosters the understanding of molecular mechanisms leading to disease development and progression. Distinct pathways involved in mitochondrial dysfunction, oxidative stress, and lysosomal function have been identified and open a unique window of opportunity for individualized treatment approaches. Read More

View Article and Full-Text PDF

Regulating inflammation associated Ferroptosis-a treatment strategy for Parkinson disease.

Curr Med Chem 2021 Apr 19. Epub 2021 Apr 19.

Institute of Research and Development, Duy Tan University, Da Nang. Vietnam.

Ferroptosis plays a critical regulatory role for a new kind of cell death initiating and developing an array of disorders like neurological diseases, acute injury of kidney, tumors and ischemia etc. This selective deposition of iron is one of the pathogenic reasons for PD and although it's underlying mechanism is still unknown. In this review, the role of neuroinflammation in Parkinson's disease (PD) leading to neurodegeneration has been discussed in detail. Read More

View Article and Full-Text PDF

Review on the Recent Progress in the Development of Fluorescent ProbesTargeting Enzymes.

Methods Appl Fluoresc 2021 Apr 19. Epub 2021 Apr 19.

College of Chemistry, Central China Normal University, Wuhan, Wuhan, Hubei, Wuhan, CHINA.

Biomolecules are very important for biological processes in a living being, performing similar or multiple tasks in and out of cells, tissues and other organisms at a particular location. The abnormal activity of particular biomolecule usually caused serious diseases such as Alzheimer's disease, Parkinson's disease, cancers, diabetes, cardiovascular diseases, arthritis etc. Hence, nondestructive and real-time visualization for certain subcellular tissue is very important for understanding the biological issues, as well as the drug administration and drug metabolism. Read More

View Article and Full-Text PDF

Water-Based Interventions for People With Neurological Disability, Autism, and Intellectual Disability: A Scoping Review.

Adapt Phys Activ Q 2021 Apr 19:1-20. Epub 2021 Apr 19.

University of South Australia.

The purpose of this study was to produce a descriptive overview of the types of water-based interventions for people with neurological disability, autism, and intellectual disability and to determine how outcomes have been evaluated. Literature was searched through MEDLINE, EMBASE, Ovid Emcare, SPORTDiscus, Google Scholar, and Google. One hundred fifty-three papers met the inclusion criteria, 115 hydrotherapy, 62 swimming, 18 SCUBA (self-contained underwater breathing apparatus), and 18 other water-based interventions. Read More

View Article and Full-Text PDF

Sign-specific stimulation 'hot' and 'cold' spots in Parkinson's disease validated with machine learning.

Brain Commun 2021 10;3(2):fcab027. Epub 2021 Mar 10.

University Health Network, Toronto, ON, Canada.

Deep brain stimulation of the subthalamic nucleus has become a standard therapy for Parkinson's disease. Despite extensive experience, however, the precise target of optimal stimulation and the relationship between site of stimulation and alleviation of individual signs remains unclear. We examined whether machine learning could predict the benefits in specific Parkinsonian signs when informed by precise locations of stimulation. Read More

View Article and Full-Text PDF

Classification of vocal tremor using updated consensus-based tremor classification criteria.

Laryngoscope Investig Otolaryngol 2021 Apr 9;6(2):261-276. Epub 2021 Mar 9.

Division of Otolaryngology - Head and Neck Surgery University of Utah Salt Lake City Utah USA.

Objectives: This study characterized the clinical phenotypes of individuals with vocal tremor (VT) using tremor classification criteria published by the International Parkinson and Movement Disorder Society (IPMDS) including laryngeal features from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS).

Methods: VT phenotypic descriptors were extracted from participant medical records from 2017 to 2019. Clinical phenotype descriptors included the: (a) chief complaint and discipline for the first appointment, (b) demographics, (c) tremor body distribution, condition, frequency, and progression, (d) exacerbating/alleviating factors, (e) treatment approaches, and (g) neurologic comorbidities. Read More

View Article and Full-Text PDF

ATP1A3-Related Disorders: An Ever-Expanding Clinical Spectrum.

Front Neurol 2021 1;12:637890. Epub 2021 Apr 1.

Department of Neurology and Center for Neurological Restoration, Neurological Institute, Cleveland Clinic, Cleveland, OH, United States.

The Na+/K+ ATPases are Sodium-Potassium exchanging pumps, with a heteromeric α-β-γ protein complex. The α3 isoform is required as a rescue pump, after repeated action potentials, with a distribution predominantly in neurons of the central nervous system. This isoform is encoded by the ATP1A3 gene. Read More

View Article and Full-Text PDF

Global Variability in Deep Brain Stimulation Practices for Parkinson's Disease.

Front Hum Neurosci 2021 31;15:667035. Epub 2021 Mar 31.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Introduction: Deep brain stimulation (DBS) has become a standard treatment option for select patients with Parkinson's disease (PD). The selection process and surgical procedures employed have, to date, not been standardized.

Methods: A comprehensive 58-question web-based survey was developed with a focus on DBS referral practices and peri-operative management. Read More

View Article and Full-Text PDF

[Inherited Creutzfeldt-Jakob disease with four-octapeptide repeat insertional mutation in the prion gene].

Rinsho Shinkeigaku 2021 Apr 17. Epub 2021 Apr 17.

Department of Neurology and Geriatrics, Kagoshima University Graduate School of Medical and Dental Sciences.

We report a case of a 60-year-old man who presented with symptoms of memory loss, gait disorder, and sluggish movement. We considered both Parkinson's disease and multiple system atrophy as possible diagnoses and consequently hospitalized the patient owing to the worsening symptoms and the development of consciousness disorder. During the course of the disease, dementia, loss of consciousness, and movement disorders worsened rapidly within one year after admission, and the patient eventually developed mutism. Read More

View Article and Full-Text PDF

Phytobezoar Associated with Levodopa-carbidopa Intestinal Gel Infusion in Patients with Parkinson's Disease: A Case Report and Literature Review.

Intern Med 2021 Apr 19. Epub 2021 Apr 19.

Department of Neurology, Hirosaki University Graduate School of Medicine, Japan.

Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is an established device-aided therapy for advanced Parkinson's disease (PD). Phytobezoar associated with LCIG is a rare device-related complication and presents with exacerbations of gastrointestinal and PD symptoms. We herein report the case of a phytobezoar that was formed at a knot on the pigtail-shaped J-tube and developed only in association with postprandial abdominal pain, similar to a feeling of a tube being pulled in without an exacerbation of PD symptoms. Read More

View Article and Full-Text PDF

Cost-effectiveness of opicapone and entacapone in reducing off-time in Parkinson's Disease patients treated with levodopa/carbidopa.

J Med Econ 2021 Apr 18. Epub 2021 Apr 18.

The CHOICE Institute, School of Pharmacy, University of Washington, Seattle, WA, USA.

Aims: To assess from a US payer perspective the relative cost-effectiveness of the catechol--methyltransferase inhibitors opicapone and entacapone when used adjunctively to levodopa/carbidopa (LD/CD) in patients with Parkinson's disease (PD), based on the drugs' effects to reduce absolute OFF-time hours in PD patients.

Materials And Methods: A Markov model was created to estimate cost-effectiveness of adjunctive opicapone treatment compared with adjunctive entacapone treatment in a synthetic cohort of 1000 patients with PD taking LD/CD. Clinical inputs were derived from clinical trials, published literature, and expert opinion. Read More

View Article and Full-Text PDF

Malignant syndromes: current advances.

Expert Opin Drug Saf 2021 Apr 17. Epub 2021 Apr 17.

Department of Neurology, First Affiliated Hospital of Chongqing Medical University, Chongqing Key Laboratory of Neurology, Chongqing, China.

Introduction: Many drugs are known to induce malignant syndromes. The most common malignant syndromes are induced by the use of antipsychotics and anesthetics and the withdrawal of anti-Parkinson drugs. As the clinical manifestations of antipsychotic malignant syndrome, Parkinson's disease hyperpyrexia syndrome and anesthetic-induced malignant syndrome are very similar, they are easily confused in the clinic. Read More

View Article and Full-Text PDF

Natural history of lung function over one year in patients with Parkinson's disease.

Respir Med 2021 Apr 16;182:106396. Epub 2021 Apr 16.

Acorda Therapeutics, Inc., Ardsley, NY, USA.

Background: Little is known about decline in lung function in Parkinson's disease (PD). To assess these changes, we assessed the changes in lung function that occurred over 12 months in patients on standard PD therapy as part of the observational cohort of an open-label study of inhaled levodopa (CVT-301) in PD.

Methods: PD patients on stable oral PD therapy and no chronic respiratory disease had spirometry and diffusing capacity of the lungs for carbon monoxide (DL) measured at 3, 6, 9, and 12 months. Read More

View Article and Full-Text PDF

Potential medicinal value of celastrol and its synthesized analogues for central nervous system diseases.

Biomed Pharmacother 2021 Apr 14;139:111551. Epub 2021 Apr 14.

Key Laboratory of Shaanxi Administration of Traditional Chinese Medicine for TCM Compatibility, and State Key Laboratory of Research & Development of Characteristic Qin Medicine Resources (Cultivation), and Shaanxi Key Laboratory of Chinese Medicine Fundamentals and New Drugs Research, and Shaanxi Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, Shaanxi University of Chinese Medicine, Xi'an 712046, Shaanxi Province, China. Electronic address:

The central nervous system (CNS) is a vital part of the human nervous system, and the incidence of CNS disease is increasing year by year, which has become a major public health problem and a prominent social problem. At present, the drugs most commonly used in the clinic are receptor regulators, and neurotransmitter inhibitors, but they are accompanied by serious side effects. Therefore, the identification of new drugs and treatment strategies for CNS disease has been a research hotspot in the medical field. Read More

View Article and Full-Text PDF

Pharmacokinetics of Opicapone and Its Metabolites in Healthy White and Chinese Subjects.

Clin Pharmacol Drug Dev 2021 Apr 17. Epub 2021 Apr 17.

Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Assessment of Clinical Drugs Risk and Individual Application Key Laboratory, Chinese Academy of Medical Sciences, Beijing, China.

Opicapone (OPC) is a third-generation catechol-O-methyltransferase inhibitor developed to treat Parkinson disease and motor fluctuations. This open-label, single-center, phase 1 study aimed to evaluate the pharmacokinetics (PK) of OPC and its metabolites when administered as single and multiple doses in healthy White and Chinese subjects. The study enrolled a total of 30 White and Chinese healthy subjects, equally balanced among groups. Read More

View Article and Full-Text PDF

NF‑κB is negatively associated with Nurr1 to reduce the inflammatory response in Parkinson's disease.

Mol Med Rep 2021 06 31;23(6). Epub 2021 Mar 31.

Department of Neurology, Second Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830063, P.R. China.

Parkinson's disease (PD) is one of the most disabling diseases of the central nervous system, seriously affecting health and quality of life for the elderly. The present study aimed to explore the effects of nuclear receptor subfamily 4 group A member 2 (Nurr1) and nuclear factor‑κB (NF‑κB) on the progression of Parkinson's disease (PD). Pheochromocytoma (PC12) cells were pretreated with the NF‑κB inhibitor quinazoline (QNZ) or transfected with small interfering (si)RNA‑NF‑κB, followed by the addition of lipopolysaccharide (LPS). Read More

View Article and Full-Text PDF

Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study.

J Neurol 2021 Apr 17. Epub 2021 Apr 17.

Department of Medical, Surgical Sciences and Advanced Technologies "GF Ingrassia", University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.

Objective: The long-duration response (LDR) to L-dopa is a sustained benefit deriving from chronic administration of therapy to patients with Parkinson's disease (PD). Almost all patients with early PD may develop the LDR to L-dopa, even if some patients could not at given dosages of the drug. Aim of this exploratory study is to investigate whether a neuroanatomical substrate may underlie the development of the of LDR using structural magnetic resonance imaging (MRI) and voxel-based morphometry (VBM) analysis. Read More

View Article and Full-Text PDF

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.

Neurol Ther 2021 Apr 17. Epub 2021 Apr 17.

Adamas Pharmaceuticals, Inc., Emeryville, CA, USA.

Introduction: Gocovri (amantadine) extended release capsules are approved for treatment of dyskinesia and as a levodopa adjunct for OFF episodes in patients with Parkinson's disease (PD). We report treatment-related effects on non-motor symptoms (NMS) assessed as secondary outcomes in two trials using the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I.

Methods: EASE LID and EASE LID 3 enrolled levodopa-treated patients with PD and ≥ 1 h/day ON time with troublesome dyskinesia. Read More

View Article and Full-Text PDF

Natural antioxidants in the management of Parkinson's disease: Review of evidence from cell line and animal models.

J Integr Med 2021 Mar 27. Epub 2021 Mar 27.

Discipline of Pharmacy, School of Health and Biomedical Sciences, Royal Melbourne Institute of Technology University, Bundoora, VIC 3084, Australia. Electronic address:

Parkinson's disease (PD) is a chronic progressive neurodegenerative disease. It results from the death of dopaminergic neurons. The pathophysiological mechanisms in idiopathic PD include the production of α-synuclein and mitochondrial respiratory function-affecting complex I, caused by reactive oxygen species. Read More

View Article and Full-Text PDF

Multi-objective data-driven optimization for improving deep brain stimulation in Parkinson's disease.

J Neural Eng 2021 Apr 16. Epub 2021 Apr 16.

Neurology, Emory University School of Medicine, 12 Executive Park Drive North East, Atlanta, Georgia, 30329, UNITED STATES.

Objective: Deep brain stimulation (DBS) is an effective treatment for Parkinson's disease (PD) but its success depends on a time-consuming process of trial-and-error to identify the optimal stimulation settings for each individual patient. Data-driven optimization algorithms have been proposed to efficiently find the stimulation setting that maximizes a quantitative biomarker of symptom relief. However, these algorithms cannot efficiently take into account stimulation settings that may control symptoms but also cause side-effects. Read More

View Article and Full-Text PDF